304 related articles for article (PubMed ID: 25613729)
21. Inhibition of cell growth and Epstein-Barr virus reactivation by CD40 stimulation in Epstein-Barr virus-transformed B cells.
Fukuda M; Satoh TA; Takanashi M; Hirai K; Ohnishi E; Sairenji T
Viral Immunol; 2000; 13(2):215-29. PubMed ID: 10893001
[TBL] [Abstract][Full Text] [Related]
22. [Diagnosis and management of EBV-positive lymphoproliferative disorders].
Arai A
Rinsho Ketsueki; 2023; 64(8):764-771. PubMed ID: 37673629
[TBL] [Abstract][Full Text] [Related]
23. Additional considerations related to the elusive boundaries of EBV-associated T/NK-cell lymphoproliferative disorders.
Fernandez-Pol S; Silva O; Natkunam Y
Haematologica; 2019 Mar; 104(3):e125-e126. PubMed ID: 30819837
[No Abstract] [Full Text] [Related]
24. Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.
Lai KY; Chou YC; Lin JH; Liu Y; Lin KM; Doong SL; Chen MR; Yeh TH; Lin SJ; Tsai CH
J Virol; 2015 Jun; 89(11):5968-80. PubMed ID: 25810549
[TBL] [Abstract][Full Text] [Related]
25. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice.
Guinness ME; Kenney JL; Reiss M; Lacy J
Cancer Res; 2000 Oct; 60(19):5354-8. PubMed ID: 11034070
[TBL] [Abstract][Full Text] [Related]
26. Identification of rare Epstein-Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling.
Shaknovich R; Basso K; Bhagat G; Mansukhani M; Hatzivassiliou G; Murty VV; Buettner M; Niedobitek G; Alobeid B; Cattoretti G
Haematologica; 2006 Oct; 91(10):1313-20. PubMed ID: 17018379
[TBL] [Abstract][Full Text] [Related]
27. Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases.
Cohen JI
Semin Hematol; 2003 Apr; 40(2):116-23. PubMed ID: 12704588
[TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor.
Kilger E; Kieser A; Baumann M; Hammerschmidt W
EMBO J; 1998 Mar; 17(6):1700-9. PubMed ID: 9501091
[TBL] [Abstract][Full Text] [Related]
29. High incidence of Epstein-Barr virus (EBV)-positive Hodgkin lymphoma and Hodgkin lymphoma-like B-cell lymphoproliferations with EBV latency profile 2 in children with interleukin-2-inducible T-cell kinase deficiency.
Bienemann K; Borkhardt A; Klapper W; Oschlies I
Histopathology; 2015 Nov; 67(5):607-16. PubMed ID: 25728094
[TBL] [Abstract][Full Text] [Related]
30. Inherited Immunodeficiencies With High Predisposition to Epstein-Barr Virus-Driven Lymphoproliferative Diseases.
Latour S; Winter S
Front Immunol; 2018; 9():1103. PubMed ID: 29942301
[TBL] [Abstract][Full Text] [Related]
31. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease.
Young L; Alfieri C; Hennessy K; Evans H; O'Hara C; Anderson KC; Ritz J; Shapiro RS; Rickinson A; Kieff E
N Engl J Med; 1989 Oct; 321(16):1080-5. PubMed ID: 2552313
[TBL] [Abstract][Full Text] [Related]
32. Expression of the simian Epstein-Barr virus-encoded latent membrane protein-1 in malignant lymphomas of SIV-infected rhesus macaques.
Blaschke S; Hannig H; Buske C; Kaup FJ; Hunsmann G; Bodemer W
J Med Virol; 2001 Sep; 65(1):114-20. PubMed ID: 11505452
[TBL] [Abstract][Full Text] [Related]
33. Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-beta 1-mediated growth inhibition in EBV-positive B cells.
Arvanitakis L; Yaseen N; Sharma S
J Immunol; 1995 Aug; 155(3):1047-56. PubMed ID: 7636179
[TBL] [Abstract][Full Text] [Related]
34. Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ.
Miyake A; Dewan MZ; Ishida T; Watanabe M; Honda M; Sata T; Yamamoto N; Umezawa K; Watanabe T; Horie R
Microbes Infect; 2008 Jun; 10(7):748-56. PubMed ID: 18538617
[TBL] [Abstract][Full Text] [Related]
35. Induction of latent membrane protein expression in in vitro Epstein-Barr virus-infected leukaemic B lymphocytes by interleukin 4 and antibodies to CD40.
Crawford DH; Thomas JA; Gregory CD; Catovsky D; Chaggar K
Leukemia; 1995 May; 9(5):747-53. PubMed ID: 7539512
[TBL] [Abstract][Full Text] [Related]
36. Secreted Oral Epithelial Cell Membrane Vesicles Induce Epstein-Barr Virus Reactivation in Latently Infected B Cells.
Lin Z; Swan K; Zhang X; Cao S; Brett Z; Drury S; Strong MJ; Fewell C; Puetter A; Wang X; Ferris M; Sullivan DE; Li L; Flemington EK
J Virol; 2016 Jan; 90(7):3469-79. PubMed ID: 26764001
[TBL] [Abstract][Full Text] [Related]
37. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
38. Cellular STAT3 functions via PCBP2 to restrain Epstein-Barr Virus lytic activation in B lymphocytes.
Koganti S; Clark C; Zhi J; Li X; Chen EI; Chakrabortty S; Hill ER; Bhaduri-McIntosh S
J Virol; 2015 May; 89(9):5002-11. PubMed ID: 25717101
[TBL] [Abstract][Full Text] [Related]
39. Age-related EBV-associated B-cell lymphoproliferative disorders and other EBV + lymphoproliferative diseases: New insights into immune escape and immunodeficiency through staining with anti-PD-L1 antibody clone SP142.
Sakakibara A; Kohno K; Ishikawa E; Suzuki Y; Shimada S; Eladl AE; Elsayed AA; Daroontum T; Satou A; Takahara T; Ohashi A; Takahashi E; Kato S; Nakamura S; Asano N
Pathol Int; 2020 Aug; 70(8):481-492. PubMed ID: 32367595
[TBL] [Abstract][Full Text] [Related]
40. A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: implications for EBV-driven lymphomagenesis in the HIV setting.
Martorelli D; Muraro E; Mastorci K; Dal Col J; Faè DA; Furlan C; Giagulli C; Caccuri F; Rusnati M; Fiorentini S; Carbone A; Caruso A; Dolcetti R
Int J Cancer; 2015 Sep; 137(6):1374-85. PubMed ID: 25704763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
